DOCSLIB.ORG

PRS) Identify OSA-Related Pathways

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PRS) Identify OSA-Related Pathways medRxiv preprint doi: https://doi.org/10.1101/2021.04.27.21255520; this version posted April 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Pathway-specific Polygenic Risk Scores (PRS) identify OSA-related pathways 2 differentially moderating genetic susceptibility to CAD 3 Goodman: Pathway-specific effects of OSA on genetic CAD risk 4 Matthew O Goodman,1,2,3 Brian E Cade,1,2,3 Neomi Shah,4 Tianyi Huang,2,5 Hassan S Dashti,3,6,7 5 Richa Saxena,1,2,3,6,7 Martin K Rutter,8,9 Peter Libby,10 Tamar Sofer,1,2 Susan Redline1,2 6 Affiliations: 7 1Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital and Harvard 8 Medical School, Boston, MA 9 2Division of Sleep Medicine, Harvard Medical School, Boston, MA 10 3Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA 11 4Icahn School of Medicine at Mount Sinai, New York, NY 12 5Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical 13 School, Boston, MA 14 6Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA 15 7Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital 16 and Harvard Medical School, Boston, MA, USA 17 8Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, 18 Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic 19 Health Science Centre, Manchester, United Kingdom 20 9Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation 21 Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom 22 10Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's 23 Hospital, Harvard Medical School, Boston, MA, USA. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.04.27.21255520; this version posted April 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Corresponding Author: 2 Matthew Goodman 3 Brigham and Women’s Hospital 4 221 Longwood Avenue 5 Boston, MA 02115 6 (617) 525-9767 7 [email protected] 8 9 Total word count: 8867 (including the title page, abstract, text, references, tables, and figures 10 legends) medRxiv preprint doi: https://doi.org/10.1101/2021.04.27.21255520; this version posted April 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 ABSTRACT 2 Background— 3 Obstructive sleep apnea (OSA) and its features, such as chronic intermittent hypoxia (IH), may 4 differentially affect specific molecular pathways and processes in the pathogenesis of coronary 5 artery disease (CAD) and influence the subsequent risk and severity of CAD events. In 6 particular, competing adverse (e.g. inflammatory) and protective (e.g. increased coronary 7 collateral blood flow) mechanisms may operate, but remain poorly understood. We hypothesize 8 that common genetic variation in selected molecular pathways influences the likelihood of CAD 9 events differently in individuals with and without OSA, in a pathway-dependent manner. 10 Methods— 11 We selected a cross-sectional sample of 471,877 participants from the UK Biobank, 12 among whom we ascertained 4,974 to have OSA, 25,988 to have CAD, and 711 to have both. 13 We calculated pathway-specific polygenic risk scores (PS-PRS) for CAD, based on 6.6 million 14 common variants evaluated in the CARDIoGRAMplusC4D genome-wide association study 15 (GWAS), annotated to specific genes and pathways using functional genomics databases. Based 16 on prior evidence of involvement with IH and CAD, we tested PS-PRS for the HIF-1, VEGF, 17 NFkB and TNF signaling pathways. 18 Results— 19 In a multivariable-adjusted logistic generalized additive model, elevated PS-PRSs for the 20 KEGG VEGF pathway (39 genes) associated with protection for CAD in OSA (interaction odds 21 ratio 0.86, p = 6E-04). By contrast, the genome-wide CAD PRS did not show evidence of 22 statistical interaction with OSA. 23 Conclusions— medRxiv preprint doi: https://doi.org/10.1101/2021.04.27.21255520; this version posted April 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 2 We find evidence that pathway-specific genetic risk of CAD differs between individuals with 3 and without OSA in a qualitatively pathway-dependent manner, consistent with the previously 4 studied phenomena whereby features of OSA may have both positive and negative effects on 5 CAD. These results provide evidence that gene-by-environment interaction influences CAD risk 6 in certain pathways among people with OSA, an effect that is not well-captured by the genome- 7 wide PRS. These results can be followed up to study how OSA interacts with genetic risk at the 8 molecular level, and potentially to personalize OSA treatment and reduce CAD risk according to 9 individual pathway-specific genetic risk profiles. 10 medRxiv preprint doi: https://doi.org/10.1101/2021.04.27.21255520; this version posted April 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 INTRODUCTION 2 Obstructive sleep apnea (OSA) is a common disorder characterized by recurrent episodes 3 of hypoxemia during sleep, sleep fragmentation, and activation of the sympathetic nervous 4 system, potentially stimulating pro-inflammatory and pro-thrombotic pathways that drive 5 atherosclerosis [1]. Epidemiological studies implicate OSA as a potentially modifiable risk factor 6 for cardiovascular disease (CVD), stimulating research aimed at quantifying the impact of OSA 7 and its treatment on both coronary artery disease (CAD) and cerebrovascular disease [2]. While 8 OSA increases the incidence of cerebrovascular disease, weaker and less consistent associations 9 support associations between OSA and incident CAD [3]. Moreover, large clinical trials of the 10 effect of positive airway pressure (PAP) treatment of OSA on composite CVD outcomes have 11 provided equivocal results, in some cases with point estimates in the direction of increased risk 12 in the treatment group [4-7]. 13 Potential explanations for disappointing results of PAP RCTs include treatment non- 14 adherence, non-optimal trial participant selection (e.g. advanced CVD at baseline) and limited 15 statistical power [8, 9]. Another possibility is that putative CVD benefits of OSA treatment may 16 vary across individuals, influenced by factors related to characteristics of OSA-related stress not 17 captured by the traditional metric of OSA severity (apnea hypopnea index, AHI), as well as by 18 underlying host characteristics [10, 11], including genetic predisposition to CVD and genetic 19 variation within known OSA pathways [12, 13]. Moreover, some features of OSA might even 20 prove protective for CVD in some individuals, and therefore treatment of OSA with PAP could 21 increase CVD risk among those individuals [14]. This hypothesis derives support from human 22 and animal studies showing that exposure to intermittent hypoxemia - a cardinal feature of OSA 1 medRxiv preprint doi: https://doi.org/10.1101/2021.04.27.21255520; this version posted April 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 - can promote collateral blood flow, reflective of well-known effects of ischemic preconditioning 2 [15]. 3 The need to develop a precision medicine-informed approach to CVD risk stratification 4 in OSA agrees with data indicating that OSA-related CVD risk varies across subgroups defined 5 by clusters of phenotypic traits [16]. A central question, and the one that we address here, is 6 whether genetic variation in CAD risk interacts with OSA features to modulate CAD risk in a 7 pathway-dependent manner. We conceptualize repeated intermittent hypoxia (IH) and 8 reoxygenation as a modifying environment for preexisting genetic risk for CAD, locating our 9 analysis within a gene-by-environment (GxE) interaction paradigm. Our pathway-level GxE 10 approach provides a new scale on which to study the genetic architecture of CAD susceptibility 11 and its modification by OSA. 12 We build on prior work that (1) identified genetic markers for CAD risk involved in 13 atherosclerosis, small vessel disease, inflammatory pathways, and angiogenesis, with evidence 14 from genome-wide association studies (GWAS), expression studies, animal experiments and 15 clinical trials [17-19]; and (2) showed the influence of IH on a variety of pathways (in positive 16 and negative directions) relevant to CAD, including redox, inflammatory and angiogenic 17 pathways [20]. 18 Our approach considers effect modification of genetic risk, aggregated to the pathway 19 level, and investigates pathway-specific polygenic risk scores (PS-PRS) for CAD.
Load more

Recommended publications
  • Ankrd9 Is a Metabolically-Controlled Regulator of Impdh2 Abundance and Macro-Assembly
    ANKRD9 IS A METABOLICALLY-CONTROLLED REGULATOR OF IMPDH2 ABUNDANCE AND MACRO-ASSEMBLY by Dawn Hayward A dissertation submitted to The Johns Hopkins University in conformity with the requirements of the degree of Doctor of Philosophy Baltimore, Maryland April 2019 ABSTRACT Members of a large family of Ankyrin Repeat Domains proteins (ANKRD) regulate numerous cellular processes by binding and changing properties of specific protein targets. We show that interactions with a target protein and the functional outcomes can be markedly altered by cells’ metabolic state. ANKRD9 facilitates degradation of inosine monophosphate dehydrogenase 2 (IMPDH2), the rate-limiting enzyme in GTP biosynthesis. Under basal conditions ANKRD9 is largely segregated from the cytosolic IMPDH2 by binding to vesicles. Upon nutrient limitation, ANKRD9 loses association with vesicles and assembles with IMPDH2 into rod-like structures, in which IMPDH2 is stable. Inhibition of IMPDH2 with Ribavirin favors ANKRD9 binding to rods. The IMPDH2/ANKRD9 assembly is reversed by guanosine, which restores association of ANKRD9 with vesicles. The conserved Cys109Cys110 motif in ANKRD9 is required for the vesicles-to-rods transition as well as binding and regulation of IMPDH2. ANKRD9 knockdown increases IMPDH2 levels and prevents formation of IMPDH2 rods upon nutrient limitation. Thus, the status of guanosine pools affects the mode of ANKRD9 action towards IMPDH2. Advisor: Dr. Svetlana Lutsenko, Department of Physiology, Johns Hopkins University School of Medicine Second reader:
    [Show full text]
  • An Amplified Fatty Acid-Binding Protein Gene Cluster In
    cancers Review An Amplified Fatty Acid-Binding Protein Gene Cluster in Prostate Cancer: Emerging Roles in Lipid Metabolism and Metastasis Rong-Zong Liu and Roseline Godbout * Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-780-432-8901 Received: 6 November 2020; Accepted: 16 December 2020; Published: 18 December 2020 Simple Summary: Prostate cancer is the second most common cancer in men. In many cases, prostate cancer grows very slowly and remains confined to the prostate. These localized cancers can usually be cured. However, prostate cancer can also metastasize to other organs of the body, which often results in death of the patient. We found that a cluster of genes involved in accumulation and utilization of fats exists in multiple copies and is expressed at much higher levels in metastatic prostate cancer compared to localized disease. These genes, called fatty acid-binding protein (or FABP) genes, individually and collectively, promote properties associated with prostate cancer metastasis. We propose that levels of these FABP genes may serve as an indicator of prostate cancer aggressiveness, and that inhibiting the action of FABP genes may provide a new approach to prevent and/or treat metastatic prostate cancer. Abstract: Treatment for early stage and localized prostate cancer (PCa) is highly effective. Patient survival, however, drops dramatically upon metastasis due to drug resistance and cancer recurrence. The molecular mechanisms underlying PCa metastasis are complex and remain unclear. It is therefore crucial to decipher the key genetic alterations and relevant molecular pathways driving PCa metastatic progression so that predictive biomarkers and precise therapeutic targets can be developed.
    [Show full text]
  • Analysis of Translating Mitoribosome Reveals Functional Characteristics of Translation in Mitochondria of Fungi
    ARTICLE https://doi.org/10.1038/s41467-020-18830-w OPEN Analysis of translating mitoribosome reveals functional characteristics of translation in mitochondria of fungi Yuzuru Itoh 1,2,4, Andreas Naschberger1,4, Narges Mortezaei1,4, Johannes M. Herrmann 3 & ✉ Alexey Amunts 1,2 1234567890():,; Mitoribosomes are specialized protein synthesis machineries in mitochondria. However, how mRNA binds to its dedicated channel, and tRNA moves as the mitoribosomal subunit rotate with respect to each other is not understood. We report models of the translating fungal mitoribosome with mRNA, tRNA and nascent polypeptide, as well as an assembly inter- mediate. Nicotinamide adenine dinucleotide (NAD) is found in the central protuberance of the large subunit, and the ATPase inhibitory factor 1 (IF1) in the small subunit. The models of the active mitoribosome explain how mRNA binds through a dedicated protein platform on the small subunit, tRNA is translocated with the help of the protein mL108, bridging it with L1 stalk on the large subunit, and nascent polypeptide paths through a newly shaped exit tunnel involving a series of structural rearrangements. An assembly intermediate is modeled with the maturation factor Atp25, providing insight into the biogenesis of the mitoribosomal large subunit and translation regulation. 1 Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, 17165 Solna, Sweden. 2 Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17165 Solna, Sweden. 3 Cell Biology, University
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Function of Deptor and Its Roles in Hematological Malignancies
    www.aging-us.com AGING 2021, Vol. 13, No. 1 Review Function of Deptor and its roles in hematological malignancies Mario Morales-Martinez1, Alan Lichtenstein2, Mario I. Vega1,2 1Molecular Signal Pathway in Cancer Laboratory, UIMEO, Oncology Hospital, Siglo XXI National Medical Center, IMSS, México, México 2Department of Medicine, Hematology-Oncology Division, Greater Los Angeles VA Healthcare Center, UCLA Medical Center, Jonsson Comprehensive Cancer Center, Los Angeles, CA 90024, USA Correspondence to: Mario I. Vega; email: [email protected] Keywords: Deptor, Multiple Myeloma, leukemia, Non-Hodgkin Lymphoma, hematological malignances Received: November 6, 2020 Accepted: December 10, 2020 Published: January 7, 2020 Copyright: © 2020 Morales-Martinez et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Deptor is a protein that interacts with mTOR and that belongs to the mTORC1 and mTORC2 complexes. Deptor is capable of inhibiting the kinase activity of mTOR. It is well known that the mTOR pathway is involved in various signaling pathways that are involved with various biological processes such as cell growth, apoptosis, autophagy, and the ER stress response. Therefore, Deptor, being a natural inhibitor of mTOR, has become very important in its study. Because of this, it is important to research its role regarding the development and progression of human malignancies, especially in hematologic malignancies. Due to its variation in expression in cancer, it has been suggested that Deptor can act as an oncogene or tumor suppressor depending on the cellular or tissue context.
    [Show full text]
  • Bioinformatics Identification of Potential Genes and Pathways in Preeclampsia Based on Functional Gene Set Enrichment Analyses
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 18: 1837-1844, 2019 Bioinformatics identification of potential genes and pathways in preeclampsia based on functional gene set enrichment analyses XUE LI and YANNING FANG Department of Obstetrics, The First People's Hospital of Jining, Jining, Shandong 272000, P.R. China Received October 24, 2018; Accepted May 2, 2019 DOI: 10.3892/etm.2019.7749 Abstract. Preeclampsia is a complication of pregnancy the sample into four distinct groups based on different incu- characterized by new-onset hypertension and proteinuria of bation time. The top 3 candidates were Toll-like receptor 2 gestation, with serious consequences for mother and infant. (TLR2), glutathione S-transferase omega 1 (GSTO1) and Although a vast amount of research has been performed on mitogen-activated protein kinase 13 (MAPK13). TLR2 and the pathogenesis of preeclampsia, the underlying mechanisms associated pathways are known to be closely associated with of this multisystemic disease have remained to be fully eluci- preeclampsia, indirectly demonstrating the applicability of dated. Data were retrieved from Gene Expression Omnibus the analytic process applied. However, the role of GSTO1 and database GSE40182 dataset. After data preprocessing, differ- MAPK13 in preeclampsia has remained poorly investigated, entially expressed genes of placental cells cultured in vitro and elucidation thereof may be a worthwhile endeavor. The from preeclampsia and normal pregnancy were determined present study may provide a basis for exploring potential novel and subjected to Kyoto Encyclopedia of Genes and Genomes genes and pathways as therapeutic targets for preeclampsia. (KEGG) enrichment analysis to identify the associated path- ways. Furthermore, functional principal component analysis Introduction (FPCA) was used to calculate the corresponding F-value of each gene.
    [Show full text]
  • Effects of Rapamycin on Social Interaction Deficits and Gene
    Kotajima-Murakami et al. Molecular Brain (2019) 12:3 https://doi.org/10.1186/s13041-018-0423-2 RESEARCH Open Access Effects of rapamycin on social interaction deficits and gene expression in mice exposed to valproic acid in utero Hiroko Kotajima-Murakami1,2, Toshiyuki Kobayashi3, Hirofumi Kashii1,4, Atsushi Sato1,5, Yoko Hagino1, Miho Tanaka1,6, Yasumasa Nishito7, Yukio Takamatsu7, Shigeo Uchino1,2 and Kazutaka Ikeda1* Abstract The mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in cell metabolism, growth, and proliferation. The overactivation of mTOR has been implicated in the pathogenesis of syndromic autism spectrum disorder (ASD), such as tuberous sclerosis complex (TSC). Treatment with the mTOR inhibitor rapamycin improved social interaction deficits in mouse models of TSC. Prenatal exposure to valproic acid (VPA) increases the incidence of ASD. Rodent pups that are exposed to VPA in utero have been used as an animal model of ASD. Activation of the mTOR signaling pathway was recently observed in rodents that were exposed to VPA in utero, and rapamycin ameliorated social interaction deficits. The present study investigated the effect of rapamycin on social interaction deficits in both adolescence and adulthood, and gene expressions in mice that were exposed to VPA in utero. We subcutaneously injected 600 mg/kg VPA in pregnant mice on gestational day 12.5 and used the pups as a model of ASD. The pups were intraperitoneally injected with rapamycin or an equal volume of vehicle once daily for 2 consecutive days. The social interaction test was conducted in the offspring after the last rapamycin administration at 5–6 weeks of ages (adolescence) or 10–11 weeks of age (adulthood).
    [Show full text]
  • BC-Box Protein Domain-Related Mechanism for VHL Protein Degradation
    BC-box protein domain-related mechanism for VHL protein degradation Maria Elena Pozzebona,1,2, Archana Varadaraja,1, Domenico Mattoscioa, Ellis G. Jaffrayb, Claudia Miccoloa, Viviana Galimbertic, Massimo Tommasinod, Ronald T. Hayb, and Susanna Chioccaa,3 aDepartment of Experimental Oncology, European Institute of Oncology, 20139 Milan, Italy; cSenology Division, European Institute of Oncology, 20141 Milan, Italy; dInternational Agency for Research on Cancer, World Health Organization, 69372 Lyon, France; and bCentre for Gene Regulation and Expression, University of Dundee, Dundee DD1 5EH, United Kingdom Edited by William G. Kaelin, Jr., Harvard Medical School, Boston, MA, and approved September 23, 2013 (received for review June 18, 2013) The tumor suppressor VHL (von Hippel–Lindau) protein is a sub- effects of the wild-type Gam1 protein (18, 20, 21), supporting the strate receptor for Ubiquitin Cullin Ring Ligase complexes (CRLs), idea that these effects may depend on Gam1 ability to act as containing a BC-box domain that associates to the adaptor Elongin substrate-receptor protein. B/C. VHL targets hypoxia-inducible factor 1α to proteasome- VHL (von Hippel–Lindau) protein is a cellular BC box-con- dependent degradation. Gam1 is an adenoviral protein, which also taining substrate receptor and associates with Cullin2-based E3 possesses a BC-box domain that interacts with the host Elongin B/C, ligases (22–24). VHL is a tumor suppressor, and its loss leads to – thereby acting as a viral substrate receptor. Gam1 associates with the von Hippel Lindau syndrome that often develops into renal both Cullin2 and Cullin5 to form CRL complexes targeting the host clear-cell carcinoma and other highly vascularized tumors (25, 26).
    [Show full text]
  • Ribosomal RNA‑Depleted RNA Sequencing Reveals the Pathogenesis of Refractory Mycoplasma Pneumoniae Pneumonia in Children
    MOLECULAR MEDICINE REPORTS 24: 761, 2021 Ribosomal RNA‑depleted RNA sequencing reveals the pathogenesis of refractory Mycoplasma pneumoniae pneumonia in children FENG HUANG1,2*, HUIFENG FAN1*, DIYUAN YANG1, JUNSONG ZHANG3, TINGTING SHI1, DONGWEI ZHANG1 and GEN LU1 1Department of Respiration, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510120; 2Institute of Human Virology, Zhongshan School of Medicine, Sun Yat‑sen University; 3Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, P.R. China Received April 17, 2020; Accepted May 28, 2021 DOI: 10.3892/mmr.2021.12401 Abstract. Pneumonia caused by Mycoplasma pneumoniae in the NRMPP and RMPP comparative groups were primarily (M. pneumoniae) is a major cause of community‑acquired enriched in ‘herpes simplex virus 1 infection’, ‘viral carcinogen‑ pneumonia in children. In some cases, M. pneumoniae pneu‑ esis’ and ‘RNA transport’. In the present study, a comprehensive monia (MPP) can develop into refractory MPP (RMPP), which analysis of the differences between the NRMPP and RMPP shows no clinical or radiological response to macrolides, and cases was performed based on rRNA‑depleted RNA‑sequencing can progress to severe and complicated pneumonia. However, techniques, and the selected genes and circRNAs may be closely the pathogenesis of RMPP remains poorly understood. The associated with the complex pathogenesis of RMPP. present study aimed to identify target genes that could be used as biomarkers for the clinical diagnosis of early‑stage RMPP Introduction through high‑throughput sequencing technology. The differences in long non‑coding (lnc)RNAs, mRNAs and circular (circ)RNAs Mycoplasma pneumoniae (M. pneumoniae) is one of the were examined between whole‑blood samples from two patients main pathogens that cause respiratory tract infections in with non‑refractory MPP (NRMPP), two patients with RMPP humans (1,2).
    [Show full text]
  • Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury’S Biological Network Based on Systematic Pharmacology
    ORIGINAL RESEARCH published: 25 June 2021 doi: 10.3389/fphar.2021.601846 Exploring the Regulatory Mechanism of Hedysarum Multijugum Maxim.-Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury’s Biological Network Based on Systematic Pharmacology Kailin Yang 1†, Liuting Zeng 1†, Anqi Ge 2†, Yi Chen 1†, Shanshan Wang 1†, Xiaofei Zhu 1,3† and Jinwen Ge 1,4* Edited by: 1 Takashi Sato, Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of 2 Tokyo University of Pharmacy and Life Cardio-Cerebral Diseases, Hunan University of Chinese Medicine, Changsha, China, Galactophore Department, The First 3 Sciences, Japan Hospital of Hunan University of Chinese Medicine, Changsha, China, School of Graduate, Central South University, Changsha, China, 4Shaoyang University, Shaoyang, China Reviewed by: Hui Zhao, Capital Medical University, China Background: Clinical research found that Hedysarum Multijugum Maxim.-Chuanxiong Maria Luisa Del Moral, fi University of Jaén, Spain Rhizoma Compound (HCC) has de nite curative effect on cerebral ischemic diseases, *Correspondence: such as ischemic stroke and cerebral ischemia-reperfusion injury (CIR). However, its Jinwen Ge mechanism for treating cerebral ischemia is still not fully explained. [email protected] †These authors share first authorship Methods: The traditional Chinese medicine related database were utilized to obtain the components of HCC. The Pharmmapper were used to predict HCC’s potential targets. Specialty section: The CIR genes were obtained from Genecards and OMIM and the protein-protein This article was submitted to interaction (PPI) data of HCC’s targets and IS genes were obtained from String Ethnopharmacology, a section of the journal database.
    [Show full text]
  • Genetics of Tuberous Sclerosis Complex: Implications for Clinical Practice
    Journal name: The Application of Clinical Genetics Article Designation: REVIEW Year: 2017 Volume: 10 The Application of Clinical Genetics Dovepress Running head verso: Caban et al Running head recto: Genetics of TSC open access to scientific and medical research DOI: http://dx.doi.org/10.2147/TACG.S90262 Open Access Full Text Article REVIEW Genetics of tuberous sclerosis complex: implications for clinical practice Carolina Caban1,2 Abstract: Tuberous sclerosis complex (TSC) is a multisystem disorder that results from hetero- Nubaira Khan1,2 zygous mutations in either TSC1 or TSC2. The primary organ systems that are affected include Daphne M Hasbani3 the brain, skin, lung, kidney, and heart, all with variable frequency, penetrance, and severity. Peter B Crino1,2 Neurological features include epilepsy, autism, and intellectual disability. There are more than 1,500 known pathogenic variants for TSC1 and TSC2, including deletion, nonsense, and missense 1Department of Neurology, 2Shriners Hospitals Pediatric Research mutations, and all pathogenic mutations are inactivating, leading to loss of function effects on Center, Temple University School of the encoded proteins TSC1 and TSC2. These proteins form a complex to constitutively inhibit 3 Medicine, Department of Neurology, mechanistic target of rapamycin (mTOR) signaling cascade, and as a consequence, mTOR signal- St. Christopher’s Hospital for Children, Drexel University College ing is constitutively active within all TSC-associated lesions. The mTOR inhibitors rapamycin For personal use only. of Medicine, Philadelphia, PA, USA (sirolimus) and everolimus have been shown to reduce the size of renal and brain lesions and improve pulmonary function in TSC, and these compounds may also decrease seizure frequency.
    [Show full text]
  • NDUFA2 Rabbit Pab
    Leader in Biomolecular Solutions for Life Science NDUFA2 Rabbit pAb Catalog No.: A8136 Basic Information Background Catalog No. The encoded protein is a subunit of the hydrophobic protein fraction of the A8136 NADH:ubiquinone oxidoreductase (complex 1), the first enzyme complex in the electron transport chain located in the inner mitochondrial membrane, and may be involved in Observed MW regulating complex I activity or its assembly via assistance in redox processes. Mutations 11kDa in this gene are associated with Leigh syndrome, an early-onset progressive neurodegenerative disorder. Alternative splicing results in multiple transcript variants. Calculated MW 8kDa/10kDa Category Primary antibody Applications WB,IHC,IF Cross-Reactivity Human, Mouse, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 4695 O43678 IHC 1:50 - 1:100 Immunogen 1:50 - 1:200 IF Recombinant fusion protein containing a sequence corresponding to amino acids 1-95 of human NDUFA2 (NP_002479.1). Synonyms NDUFA2;B8;CD14;CIB8 Contact Product Information 400-999-6126 Source Isotype Purification Rabbit IgG Affinity purification [email protected] www.abclonal.com.cn Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using NDUFA2 antibody (A8136) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020). Exposure time: 30s. Immunohistochemistry of paraffin- Immunohistochemistry of paraffin- Immunofluorescence analysis of NIH/3T3 embedded human esophagus using embedded human liver cancer using cells using NDUFA2 antibody (A8136) at NDUFA2 antibody (A8136) at dilution of NDUFA2 antibody (A8136) at dilution of dilution of 1:100.
    [Show full text]